A Phase 3 interventional study of Infanrix hexa™ in Poliomyelitis, Tetanus and Acellular Pertussis, sponsored by GlaxoSmithKline. Completed at 4 sites in India. Open to participants aged 6 Weeks to 10 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-02.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Poliomyelitis.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, this one is the 12th largest by enrollment, is the only one that started in 2012, is one of 7 in phase 3, and was the 7th registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →None of the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis is open now. The open studies under Poliomyelitis, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 6 Weeks to 10 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2012.
This study's enrollment of 224 is below the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 467 across the 14 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 14 have an industry lead sponsor. The 2 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.
44 studies in Poliomyelitis by GlaxoSmithKline: none open now, none under way, none of them phase 3. Of 43 finished, 30 (70%) have results posted.
Among the 44 studies in Poliomyelitis by GlaxoSmithKline, this one is the 30th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2012, is one of 20 in phase 3, and was the 32nd registered.
GlaxoSmithKline’s Poliomyelitis studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Poliomyelitis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 44 in Poliomyelitis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the immunogenicity and safety of Infanrix hexa™ (DTPa-HBV-IPV/Hib) when administered as a primary vaccination course to Indian infants according to a 6-10-14 weeks or a 2-4-6 months schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects must satisfy ALL the following criteria at study entry:
Exclusion Criteria:
The following criteria should be checked at the time of study entry. If ANYexclusion criterion applies, the subject must not be included in the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 6, 10 and 14 weeks of age, administered intramuscularly in the right side of the thigh.
Biological: Infanrix hexa™
Healthy male or female subjects, aged between and including 6 and 10 weeks of age at the time of first vaccination, who received 3 doses of Infanrix hexa™ vaccine at 2, 4 and 6 months of age, administered intramuscularly in the right side of the thigh.
Biological: Infanrix hexa™
Intramuscular, three doses
Also known as: DTPa-HBV-IPV/Hib
Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T) Antigens
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Seroprotected Subjects Against Hepatitis B (HBs)
A seroprotected subject was defined as a vaccinated subject with anti-HBS antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Seroprotected Subjects Against Poliovirus (Polio) Types 1,2,3 Antigens
A seroprotected subject was defined as a subject with anti-Poliovirus 1,2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens
A seroprotected subject was defined as a subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Subjects With Vaccine Response for Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA) and Pertactin (PRN)
Vaccine response was defined as : For initially seronegative subjects (S-), antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at 1 month after the third dose; For initially seropositive subjects (S+): antibody concentration at 1 month after the third dose ≥ 1 fold increase in the pre-vaccination antibody concentration.
Time frame: One month post Dose 3 (Month 3 or Month 5)
Anti-D and Anti-T Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Anti-HBs Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Anti-Polio Types 1, 2, 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: One month post Dose 3 (Month 3 or Month 5)
Anti-PRP Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
Time frame: One month post Dose 3 (Month 3 or Month 5)
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Time frame: One month post Dose 3 (Month 3 or Month 5)
Number of Seroprotected Subjects Against Polio Type 1, 2 and 3 Antigens
A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).
Time frame: At Month 0
Number of Seropositive Subjects for Anti-PT, Anti-FHA and Anti-PRN
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
Time frame: At Month 0
Number of Seroprotected Subjects Against Anti-HBs Antigens
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.
Time frame: At Month 0
Anti-Polio Types 1, 2 and 3 Antibody Titers
Antibody titers were presented as geometric mean titers (GMTs).
Time frame: At Month 0
Anti-PT, Anti-FHA and Anti-PRN Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
Time frame: At Month 0
Anti-HBs Antibody Concentrations
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
Time frame: At Month 0
Number of Subjects With Any Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of any particular symptom regardless of intensity grade.
Time frame: During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)
Number of Subjects With Solicited General Symptoms
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = incidence of any particular symptom regardless of intensity grade or relationship to study vaccination.
Time frame: During the 4-day (Days 0-3) post-vaccination period after each dose and across doses: Up to Month 2 (Infanrix Hexa 6-10-14 Group) or Month 4 (Infanrix Hexa 2-4-6 Group)
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
Time frame: During the 31-day (Days 0-30) post-vaccination period: Up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group)
Number of Subjects With Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (from Month 0 up to Month 3 (Infanrix Hexa 6-10-14 Group) or Month 5 (Infanrix Hexa 2-4-6 Group))
| Milestone | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Started | 112 | 112 |
| Completed | 111 | 112 |
| Not completed | 1 | 0 |
| Withdrew: Migrated/moved from study area | 1 | 0 |
A seroprotected subject was defined as a vaccinated subject with anti-D and anti-T antibody concentration greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-D | 105 | 106 |
| Anti-T | 105 | 106 |
A seroprotected subject was defined as a vaccinated subject with anti-HBS antibody concentration ≥ 10 milli-international units per milliliter (mIU/mL).
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Number of Seroprotected Subjects Against Hepatitis B (HBs) | 101 | 104 |
A seroprotected subject was defined as a subject with anti-Poliovirus 1,2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-Polio 1 | 99 | 99 |
| Anti-Polio 2 | 77 | 88 |
| Anti-Polio 3 | 73 | 79 |
A seroprotected subject was defined as a subject with anti-PRP antibody concentration ≥ 0.15 micrograms per milliliter (µg/mL).
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Number of Seroprotected Subjects Against Polyribosyl-ribitol Phosphate (PRP) Antigens | 104 | 105 |
Vaccine response was defined as : For initially seronegative subjects (S-), antibody concentration ≥ 5 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL) at 1 month after the third dose; For initially seropositive subjects (S+): antibody concentration at 1 month after the third dose ≥ 1 fold increase in the pre-vaccination antibody concentration.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PT, S- | 61 | 67 |
| Anti-PT, S+ | 44 | 36 |
| Anti-FHA, S- | 12 | 12 |
| Anti-FHA, S+ | 86 | 88 |
| Anti-PRN, S- | 86 | 89 |
| Anti-PRN, S+ | 18 | 14 |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in international units per milliliter (IU/mL).
| IU/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-D | 2.334 (2.049 to 2.659) | 3.726 (3.26 to 4.258) |
| Anti-T | 3.307 (2.925 to 3.739) | 4.904 (4.378 to 5.493) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in milli-international units per milliliter (mIU/mL).
| mIU/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 1695.7 (1395.2 to 2060.9) | 3314.5 (2645.2 to 4153.1) |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-Polio 1 | 884.3 (666.6 to 1173.1) | 1799.2 (1429 to 2265.5) |
| Anti-Polio 2 | 840.2 (616.9 to 1144.2) | 2138.7 (1658.1 to 2758.7) |
| Anti-Polio 3 | 923.7 (691.9 to 1233.2) | 2245.5 (1866.1 to 2702.1) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in µg/mL.
| µg/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PRP Antibody Concentrations | 2.697 (2.176 to 3.343) | 5.404 (4.168 to 7.006) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
| EL.U/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PT | 107.3 (96.6 to 119.1) | 108.2 (97.4 to 120.2) |
| Anti-FHA | 293.7 (259.4 to 332.6) | 369.3 (335.5 to 406.5) |
| Anti-PRN | 224.4 (194.2 to 259.3) | 243.6 (213.2 to 278.4) |
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PT | 105 | 106 |
| Anti-FHA | 105 | 106 |
| Anti-PRN | 105 | 106 |
A seroprotected subject was defined as a subject with anti-Polio type 1, 2 and 3 antibody titers ≥ 8 effective dose, for 50% of people receiving the vaccine (ED50).
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-Polio 1 | 71 | 70 |
| Anti-Polio 2 | 38 | 42 |
| Anti-Polio 3 | 23 | 30 |
A seropositive subject was defined as a subject with anti-PT, anti-FHA and anti-PRN antibody concentrations ≥ 5 EL.U/mL.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PT | 44 | 37 |
| Anti-FHA | 89 | 90 |
| Anti-PRN | 19 | 15 |
A seroprotected subject was defined as a subject with anti-HBs antibody concentrations ≥ 10 mIU/mL.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Number of Seroprotected Subjects Against Anti-HBs Antigens | 14 | 13 |
Antibody titers were presented as geometric mean titers (GMTs).
| Titers | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-Polio 1 | 53.5 (33.5 to 85.3) | 31.9 (21.5 to 47.2) |
| Anti-Polio 2 | 32.5 (19.2 to 55) | 36.2 (22.2 to 59) |
| Anti-Polio 3 | 8 (5.9 to 10.8) | 11.9 (8.3 to 17) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in EL.U/mL.
| EL.U/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-PT | 5 (4.2 to 6) | 4.6 (3.8 to 5.6) |
| Anti-FHA | 18.7 (15 to 23.3) | 20.1 (16.1 to 25.2) |
| Anti-PRN | 3.4 (2.9 to 3.9) | 3.2 (2.8 to 3.7) |
Antibody concentrations were presented as geometric mean concentrations (GMCs), expressed in mIU/mL.
| mIU/mL | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Anti-HBs Antibody Concentrations | 5.9 (4.2 to 8.3) | 5.6 (4.1 to 7.7) |
Assessed solicited local symptoms were pain, redness and swelling. Any = incidence of any particular symptom regardless of intensity grade.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Any Pain, Dose 1 | 23 | 11 |
| Any Redness, Dose 1 | 3 | 1 |
| Any Swelling, Dose 1 | 7 | 4 |
| Any Pain, Dose 2 | 13 | 3 |
| Any Redness, Dose 2 | 0 | 1 |
| Any Swelling, Dose 2 | 2 | 2 |
| Any Pain, Dose 3 | 10 | 6 |
| Any Redness, Dose 3 | 3 | 0 |
| Any Swelling, Dose 3 | 2 | 3 |
| Any Pain, Across doses | 28 | 15 |
| Any Swelling, Across doses | 6 | 2 |
| Any Redness, Across doses | 8 | 9 |
Assessed solicited general symptoms were drowsiness, irritability/fussiness, loss of appetite and temperature \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = incidence of any particular symptom regardless of intensity grade or relationship to study vaccination.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Any Drowsiness, Dose 1 | 0 | 2 |
| Any Irritability/fussiness, Dose 1 | 8 | 5 |
| Any Loss of appetite, Dose 1 | 1 | 3 |
| Any Temperature/(Axillary), Dose 1 | 10 | 7 |
| Any Drowsiness, Dose 2 | 0 | 0 |
| Any Irritability/fussiness, Dose 2 | 2 | 5 |
| Any Loss of appetite, Dose 2 | 0 | 1 |
| Any Temperature/(Axillary), Dose 2 | 5 | 7 |
| Any Drowsiness, Dose 3 | 0 | 0 |
| Any Irritability/fussiness, Dose 3 | 3 | 3 |
| Any Loss of appetite, Dose 3 | 1 | 1 |
| Any Temperature/(Axillary), Dose 3 | 3 | 6 |
| Any Drowsiness, Across doses | 0 | 2 |
| Any Irritability/fussiness, Across doses | 13 | 10 |
| Any Loss of appetite, Across doses | 2 | 5 |
| Any Temperature/(Axillary), Across doses | 17 | 17 |
An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 40 | 25 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Number of Subjects With Serious Adverse Events (SAEs) | 2 | 3 |
Collected over Solicited symptoms: during the 4-day (Days 0-3) post-vaccination period. Unsolicited AEs: during the 31-day (Days 0-30) post-vaccination period. SAEs: during the entire study period (from Month 0 to Month 3 or Month 5).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Infanrix Hexa 6-10-14 Group | 0/112 (0%) | 2/112 (1.8%) | 45/112 (40.2%) |
| Infanrix Hexa 2-4-6 Group | 0/112 (0%) | 3/112 (2.7%) | 36/112 (32.1%) |
| Event | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| Lower respiratory tract infectionInfections and infestations | 0/112 | 2/112 |
| BronchiolitisInfections and infestations | 1/112 | 0/112 |
| PneumoniaInfections and infestations | 1/112 | 1/112 |
| Event | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group |
|---|---|---|
| PainGeneral disorders | 28/112 | 15/112 |
| PyrexiaGeneral disorders | 18/112 | 17/112 |
| Upper respiratory tract infectionInfections and infestations | 18/112 | 11/112 |
| IrritabilityPsychiatric disorders | 13/112 | 10/112 |
| SwellingGeneral disorders | 8/112 | 9/112 |
| ErythemaSkin and subcutaneous tissue disorders | 6/112 | 2/112 |
| RhinitisInfections and infestations | 4/112 | 6/112 |
| Age, Continuous(Weeks) | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group | Total |
|---|---|---|---|
| Mean | 6.7 ± 1.04 | 6.8 ± 1.13 | 6.75 ± 1.08 |
| Sex: Female, Male(Participants) | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group | Total |
|---|---|---|---|
| Female | 52 | 52 | 104 |
| Male | 60 | 60 | 120 |
| Race/Ethnicity, Customized(Participants) | Infanrix Hexa 6-10-14 Group | Infanrix Hexa 2-4-6 Group | Total |
|---|---|---|---|
| Asian-Central/South Asian heritage | 112 | 112 | 224 |
Plan to share: Yes — IPD is available via the Clinical Study Data Request site (click on the link provided below)
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Apr 2012 to primary completion in Feb 2013, 10 months.
Results were first posted in Jan 2019, 5 years 11 months after primary completion. A results delay was requested in Apr 2013.
Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 10 months is below that.
Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine